Khê Hoang-Xuan
Khê Hoang-Xuan is an expert in Neurology at Pitié-Salpêtrière Hospital (France). As of October 2026, ScienceLeadR ranks Khê Hoang-Xuan in the top 1% of experts worldwide for Glioma, Nervous System Neoplasms and Lymphoma. Khê Hoang-Xuan has authored 501 publications, the most recent in 2026, and is an investigator in 16 clinical trials, 3 of them ongoing. SLR score: 1,580 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Oncology - Hematology - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1990 - 2026
Number : 501
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Medium-Term Cognitive Outcome in Patients With CNS Lymphomas Treated With Chimeric Antigen Receptor T-Cell Therapy. PMID 42826379 — cells, lymphoma, executive function, receptors, antigen, receptors, chimeric antigen, therapeutics, memory, t-lymphocytes, neurology, receptors, antigen, t-cell, car-t cell | Neurology | 2026 | 0 |
| Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma. PMID 42776058 — brain neoplasms, lymphoma, treatment failure, central nervous system, proteomics, therapeutics, nervous system, proteome, liquid biopsy, plasma | Neuro Oncol | 2026 | 0 |
| Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma. PMID 42757517 — cells, lymphoma, neoplasms, cognitive dysfunction, central nervous system, therapeutics, nervous system, antibodies, bispecific | Curr Opin Oncol | 2026 | 0 |
| Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study. PMID 42430569 — hematology, ifosfamide, lymphoma, cytarabine, aged, rituximab, genes, arac, procarbazine, therapeutics, etoposide, methotrexate | Hematol Oncol | 2026 | 0 |
| Radiological and FDG-PET imaging features of Epstein-Barr virus-positive primary central nervous system lymphomas. PMID 42410107 — lymphoma, positron-emission tomography, neurosurgery, central nervous system, herpesvirus 4, human, viruses, diagnosis, nervous system, wounds and injuries, neurology | J Neurol | 2026 | 0 |
Clinical Studies 16
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study in newly diagnosed glioblastoma patients that aims at testing the efficacy of Optune (Tumor Treating Fields) together with temozolomide and pembrolizumab compared to Optune (Tumor Treating Fields) together with temozolomide and placebo (ie inactive substance) 2024-513550-30-00 — research design, temozolomide, neoplasms, maintenance, glioblastoma, therapeutics | Phase 3 | Recruiting | 2025 |
| EF 41 KEYNOTE D58 Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma NCT06556563 — saline solution, temozolomide, neoplasms, maintenance, solutions, immunotherapy, glioblastoma, therapeutics | Phase 3 | Recruiting | 2025 |
| Dose Dense Re challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma NCT05135858 — injections, body surface area, administration, intravenous, lymphoma, central nervous system, nervous system, methotrexate | Phase 1 | Recruiting | 2022 |
LeadR Networks
Main global connection map